Document is current
Any future updates will be listed below
-
Authors
Umemoto, Akio
Kuwada, Takeshi
Murata, Koichi https://orcid.org/0000-0002-7896-3937
Shiokawa, Masahiro https://orcid.org/0000-0001-6436-3888
Ota, Sakiko
Murotani, Yoshiki
Itamoto, Akihiro
Nishitani, Kohei
Yoshitomi, Hiroyuki
Fujii, Takayuki
Onishi, Akira
Onizawa, Hideo
Murakami, Kosaku
Tanaka, Masao
Ito, Hiromu
Seno, Hiroshi
Morinobu, Akio
Matsuda, Shuichi
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (21K09298)
Takeda Medical Research Foundation
Nakatomi Foundation
- License Information
-
More Information
Article History
Received: 17 October 2022
Accepted: 6 February 2023
First Online: 17 February 2023
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki, with approval from the ethics committee of Kyoto University Hospital (E1308). Written informed consent was obtained from all the participants. All animal studies were conducted in accordance with the principles of the Kyoto University Committee of Animal Resources (Medkyo22245), which is based on the International Guiding Principles for Biomedical Research Involving Animals.
: The Department of Advanced Medicine for Rheumatic Diseases is supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan, and five pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd, UCB Japan Co. Ltd, Asahi Kasei Pharma Corp., and AYUMI Pharmaceutical Co.). This study was conducted as an investigator initiated the study. These companies had no role in the design of the study, the collection or analysis of data, the writing of the manuscript, or the decision to submit the manuscript for publication.All authors have declared no conflict of interest.
